You are here

Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.

Last updated on December 6, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Patras, Pellopoese, Greece
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neovascular Age-related Macular Degeneration
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-90 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

adults with neovascular age-related macula degeneration

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

according to SmPC

NCT00858208
Pfizer
Completed
Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Age Related Macular Degeneration
NCT01691261
All Genders
60+
Years
London,
Neovascular Age-related Macular Degeneration
NCT00549055
All Genders
0+
Years
Multiple Sites
Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD), Early Markers
NCT00902785
All Genders
50+
Years
Multiple Sites
Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.
Long-Term Non-Interventional Study To Investigate The Efficacy And Safety Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice.
Efficacy and safety of MACUGEN in patients suffering from neovascular age-related macular degeneration in routine clinical practice at least as good as demonstrated in randomized multicenter clinical trials.
Eligible patients in routine clinical practice
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with Age-related Macula degeneration
Neovascular Age-related Macular Degeneration
Drug: pegaptanib sodium
pegaptanib sodium intravitreal injection every 6 weeks for 2 years
Patients with neovascular Age-Related Macula Degeneration
Intervention: Drug: pegaptanib sodium
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
86
April 2011
April 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

adults with neovascular age-related macula degeneration

Exclusion Criteria:

according to SmPC

Sexes Eligible for Study: All
18 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Greece
 
 
NCT00858208
A5751028
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now